More articles about Business, Policy & Funding

Illumina also said it is developing a regulated version of its high-throughput NovaSeq system to address growing demand for a diagnostic platform with higher throughput.

Illumina will grant Roche rights to develop and distribute IVD tests on its Dx sequencing instruments, while Roche will help expand the CDx claims for Illumina's solid tumor panel.

The deal gives Definitive Healthcare a foothold in the genomics market as it looks to build its own genomic data pipeline to serve through PatientFinder's CohortBuilder tool.

In December, the companies agreed to develop CRISPR tools with the aim of generating new engineered cell lines for the biopharmaceutical industry.

The European firms will collaborate to scale up manufacturing of proprietary silicon chips used in Evonetix's benchtop DNA synthesis platform.

The patent, which was awarded Jan. 7, covers cell-free DNA-based diagnostic methods, including those used in transplant medicine.

Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.

The company recently changed its name from Interpace Diagnostics as it expands its focus to include drug discovery and development services.

Test volume for its Cologuard test was up 63 percent year over year, while test volume for Genomic Health's Oncotype DX jumped 14 percent.